Providence St. Johns Health Center

Santa Monica, California 90404

2 studies enrolling now · 8 studies all time

What they study most

Breast Cancer, COVID-19 Pneumonia, Carcinoma, Transitional Cell, Chronic Ischemic Stroke, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma, Overactive Bladder, Refractory Hematologic Malignancy, Refractory Primary Central Nervous System Lymphoma, Relapsed Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Solid Tumors

Studies at this site

• CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) — Recruiting now
• uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto — Recruiting now
• A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) — Paused
• Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer — Running, not enrolling
• Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies — Completed
• A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia — Completed
• Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial — Status unconfirmed
• Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke — Completed